Video Experimental Relacionado
Updated: Mar 14, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.7K
Línea de tiempo: Tratamiento dirigido del virus de la hepatitis C
1Editor, Trends in Microbiology.
Cell
|September 24, 2016
Resumen
La infección por el virus de la hepatitis C (VHC) conduce a la cirrosis hepática y al cáncer. La investigación sobre el ciclo de vida viral permitió el desarrollo de antivirales de acción directa, mejorando las opciones de tratamiento.
Área de la Ciencia:
- Virología
- Hepatología
- Desarrollo de drogas
Sus antecedentes:
- La infección crónica por el virus de la hepatitis C (VHC) es una de las principales causas de cirrosis hepática y cáncer.
- Los primeros tratamientos para el VHC a menudo no eran específicos y estaban asociados con una toxicidad significativa.
- La comprensión del ciclo de vida del VHC fue crucial para el desarrollo de terapias dirigidas.
Objetivo del estudio:
- Para resaltar los avances clave en la comprensión de la replicación del VHC.
- Mostrar el desarrollo de antivirales de acción directa (AAD) para el tratamiento del VHC.
- Para reconocer las contribuciones de investigadores como Ralf Bartenschlager, Charles Rice y Michael Sofia.
Principales métodos:
- Elucidación del ciclo de vida del virus de la hepatitis C.
- Desarrollo de nuevos compuestos antivirales dirigidos a la replicación viral.
- Ensayos clínicos que evalúan la eficacia y la seguridad de los antivirales de acción directa.
Principales resultados:
- Avances significativos en la comprensión de los mecanismos de replicación del VHC.
- Desarrollo y aprobación exitosos de antivirales de acción directa.
- Mejora de los resultados del tratamiento y reducción de la toxicidad en pacientes con infección crónica por el VHC.
Conclusiones:
- La comprensión detallada de la replicación del VHC allanó el camino para DAA efectivos.
- Los antivirales de acción directa representan un gran avance en el tratamiento de la hepatitis C crónica.
- El trabajo que condujo a los AAD ha sido reconocido con prestigiosos premios, subrayando su impacto clínico.
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:10Retrovirus Life Cycles
50.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.2K
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
615
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
01:24Modified-Release Drug Delivery Systems: Site-Targeted
70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70